Literature DB >> 16616425

C/EBPalpha: a tumour suppressor in multiple tissues?

Mikkel Bruhn Schuster1, Bo Torben Porse.   

Abstract

The CCATT/enhancer binding protein alpha, C/EBPalpha, is a key transcription factor involved in late differentiation events of several cell types. Besides acting as a classical transcription factor, C/EBPalpha is also a well-characterized inhibitor of mitotic growth in most cell lines tested. In line with its anti-mitotic properties, C/EBPalpha has been shown to interact with, and alter the activities of, several cell cycle related proteins and a number of models as to the mechanistics of C/EBPalpha-mediated growth repression have been proposed. More recently, several reports have indicated that C/EBPalpha acts as a tumour suppressor in the hematopoietic system and that mutation within C/EBPalpha is sufficient to induce tumourigenesis. Here, we will review these data and probe the possibility that C/EBPalpha also act as a tumour suppressor in other C/EBPalpha-expressing tissues.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16616425     DOI: 10.1016/j.bbcan.2006.02.003

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  49 in total

1.  The ubiquitin ligase Fbxw7 controls adipocyte differentiation by targeting C/EBPalpha for degradation.

Authors:  Maria T Bengoechea-Alonso; Johan Ericsson
Journal:  Proc Natl Acad Sci U S A       Date:  2010-06-01       Impact factor: 11.205

Review 2.  RNA activation technique and its applications in cancer research.

Authors:  Xiao-Yu Wang; Long Yuan; Yan-Ling Li; Si-Jie Gan; Lin Ren; Fan Zhang; Jun Jiang; Xiao-Wei Qi
Journal:  Am J Cancer Res       Date:  2018-04-01       Impact factor: 6.166

Review 3.  Regulation and deregulation of mRNA translation during myeloid maturation.

Authors:  Arati Khanna-Gupta
Journal:  Exp Hematol       Date:  2010-11-18       Impact factor: 3.084

4.  Reintroduction of CEBPA in MN1-overexpressing hematopoietic cells prevents their hyperproliferation and restores myeloid differentiation.

Authors:  Ayten Kandilci; Gerard C Grosveld
Journal:  Blood       Date:  2009-06-26       Impact factor: 22.113

5.  C/EBPα expression is downregulated in human nonmelanoma skin cancers and inactivation of C/EBPα confers susceptibility to UVB-induced skin squamous cell carcinomas.

Authors:  Elizabeth A Thompson; Songyun Zhu; Jonathan R Hall; John S House; Rakesh Ranjan; Jeanne A Burr; Yu-Ying He; David M Owens; Robert C Smart
Journal:  J Invest Dermatol       Date:  2011-02-24       Impact factor: 8.551

Review 6.  A tumor suppressor role for C/EBPα in solid tumors: more than fat and blood.

Authors:  A R Lourenço; P J Coffer
Journal:  Oncogene       Date:  2017-05-15       Impact factor: 9.867

7.  Down-regulation of micro-RNA-1 (miR-1) in lung cancer. Suppression of tumorigenic property of lung cancer cells and their sensitization to doxorubicin-induced apoptosis by miR-1.

Authors:  Mohd W Nasser; Jharna Datta; Gerard Nuovo; Huban Kutay; Tasneem Motiwala; Sarmila Majumder; Bo Wang; Saul Suster; Samson T Jacob; Kalpana Ghoshal
Journal:  J Biol Chem       Date:  2008-09-25       Impact factor: 5.157

8.  Reduced expression of C/EBP alpha protein in hepatocellular carcinoma is associated with advanced tumor stage and shortened patient survival.

Authors:  Hsi-Huang Tseng; Yaw-Huei Hwang; Kun-Tu Yeh; Jan-Gowth Chang; Yao-Li Chen; Hsin-Su Yu
Journal:  J Cancer Res Clin Oncol       Date:  2008-07-29       Impact factor: 4.553

9.  C/EBPalpha redirects androgen receptor signaling through a unique bimodal interaction.

Authors:  J Zhang; M Gonit; M D Salazar; A Shatnawi; L Shemshedini; R Trumbly; M Ratnam
Journal:  Oncogene       Date:  2009-11-09       Impact factor: 9.867

10.  Protein kinase Cdelta stimulates proteasome-dependent degradation of C/EBPalpha during apoptosis induction of leukemic cells.

Authors:  Meng Zhao; Xu-Fang Duan; Xu-Yun Zhao; Bo Zhang; Ying Lu; Wei Liu; Jin-Ke Cheng; Guo-Qiang Chen
Journal:  PLoS One       Date:  2009-08-07       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.